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Impact of initial dialysis modality and modality switches on
Medicare expenditures of end-stage renal disease patients.
Background. The number of end-stage renal disease (ESRD)
enrollees and Medicare expenditures have increased dramati-
cally. Pathways and associated Medicare expenditures in ESRD
treatment need to be examined to potentially improve the
efficiency of care.
Methods. This study examines the impact of initial dialysis
modality choice and subsequent modality switches on Medi-
care expenditure in a 3-year period. The Dialysis Morbidity and
Mortality Study Wave 2 data by the United States Renal Data
System (USRDS) is used along with the USRDS Core CD and
USRDS claims data.
Results. A total of 3423 incident dialysis patients (approx-
imately equal number of peritoneal dialysis and hemodialy-
sis) were included in the analysis. Unadjusted average annual
Medicare expenditure (in 2004 dollars) for peritoneal dialysis
as first modality was $53,277 (95% CI $50,626-$55,927), and
$72,189 (95% CI $67,513-$76,865) for hemodialysis. Compared
to “hemodialysis, no switch” subgroup, “peritoneal dialysis, no
switch” had a significantly lower annual expenditure ($44,111
vs. $72,185) (P < 0.001). “Peritoneal dialysis, with at least one
switch” and “hemodialysis, with at least one switch” had a lower
or similar annual expenditure of $66,639 and $72,335, respec-
tively. After adjusting for patient characteristics, annual Medi-
care expenditure was still significantly lower for patients with
peritoneal dialysis as the initial modality ($56,807 vs. $68,253)
(P < 0.001). Similarly, compared to “hemdialysis, no switch”
subgroup, “peritoneal dialysis, no switch” and “peritoneal dial-
ysis, with at least one switch” had a significantly lower total
expenditure. Further analysis showed that time-to-first switch
also independently impacted total expenditure.
Conclusion. Initial modality choice (peritoneal dialysis or
hemodialysis) and subsequent modality switches had significant
implications for Medicare expenditure on ESRD treatments.
The progressive increase in patients with end-stage re-
nal disease (ESRD) [1] and the high relative expenditures
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associated with the management of ESRD compared to
other Medicare beneficiaries [2, 3] have invited scrutiny
of the cost elements of the various therapies applied in
this patient population [2–21]. It is generally recognized
that renal transplantation offers the best survival advan-
tage, patient rehabilitation and quality of life, and cost
effectiveness of all renal replacement therapies [4, 22–
24]. Regrettably, renal transplantation is hampered by
limitations of available organs, patient suitability and re-
turn to dialysis after a number of years. This results in the
majority of patients in the United States requiring dialy-
sis therapy as either the only form of renal replacement
or as a recourse before renal transplant or after allograft
failure.
Hemodialysis and peritoneal dialysis are considered
equivalent therapies in terms of patient survival [25–
35], differing in terms of logistic implementation with
peritoneal dialysis being home-based self-care dialysis
while hemodialysis in the United States is predomi-
nantly center-based assisted care. Differences between
the modalities also extend to the role of patients in modal-
ity selection and their overall profile as it pertains to co-
morbidities [36]. Several previous studies have looked at
the differences in expenditure between the two dialysis
modalities in the United States and various parts of the
world finding that in general expenditure are lower in pa-
tients on self-care home-based therapies than in patients
on assisted center-based hemodialysis [3, 5, 6, 9, 11–16,
18, 20, 21, 37–41]. The elements contributing to these dif-
ferences in expenditure have been related to either the
costs of therapy delivery or the differing requirements
of patients for expensive medications such as the lower
needs of peritoneal dialysis patients for erythropoietin
use for equivalent levels of anemia correction as patients
on hemodialysis [42]. It is recognized, however, that the
clinical journey of a patient with ESRD is not limited to a
single modality, but that the clinical needs of the patient
are frequently better served by sequential use of differ-
ent modalities either because of changing medical condi-
tions, occurrence of complications, or patient choice and
preference [43]. Any transfer between modalities would
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expectedly have an effect on the overall expenditures re-
lated to the care of the patient as we now have a mixture
of modality use and the cost of transfer as a change in
modality is invariably associated with the cost of change
in dialysis access. The purpose of the present paper is to
evaluate the costs of the two modalities and the impact of
initial modality choice and modality switch on the overall
Medicare expenditure taking into account the “residence
time” on each modality as a factor influencing the expen-
diture calculation.
METHODS
Data
This study uses the Dialysis Morbidity and Mortality
Study (DMMS) Wave 2 data, collected by the United
States Renal Data System (USRDS), to examine the im-
pact of the initial modality choice and of switching modal-
ities on Medicare’s ESRD expenditures. The USRDS is
a national data system that collects, analyzes, and dis-
tributes information on the incidence, prevalence, treat-
ment, morbidity, and mortality of end-stage renal disease
in the United States [44]. It provides clinical, demo-
graphic, and Medicare claims information for almost all
ESRD patients, except those covered by the U.S. Depart-
ment of Veterans Affairs.
The DMMS is a special study to collect demographic,
comorbidity, laboratory, treatment, socioeconomic, and
insurance information for a large random sample of dialy-
sis patients [44]. The DMMS study contains four waves of
data collection over a 3-year period. DMMS Wave 2 data
is used in this analysis. The DMMS Wave 2 is a prospec-
tive observational database consisting of information on
a random sample of incident ESRD patients initiating
dialysis in 1996 and early 1997. About 4000 patients were
captured at baseline in Wave 2. Approximately equal
numbers of peritoneal dialysis and hemodialysis patients
were included.
To examine Medicare’s ESRD expenditures associated
with different initial modalities, and the subsequent treat-
ment pathways in the 3-year study period, the DMMS
Wave 2 data were merged with the modality history file
in the USRDS Core CD via unique patient identifiers
(encrypted) to obtain information on switching patterns
following the initial dialysis modality. The DMMS Wave 2
data were also merged with the USRDS claims data (i.e.,
claims in the institutional file and the physician/supplier
files) to get the 3-year Medicare expenditures for each
ESRD beneficiary.
Patients and follow-up
Patients were included in the analysis unless they
were missing a valid patient identifier, missing values
in the dialysis start date or the initial dialysis modality,
or lacking information on Medicare claims. Initial treat-
ment modality was assigned as follows: patients start-
ing on center-hemodialysis were assigned hemodialysis,
whereas patients beginning with continuous ambulatory
peritoneal dialysis (CAPD) or continuous cycling peri-
toneal dialysis (CCPD) were classified as peritoneal dial-
ysis. Patients on home-hemodialysis were excluded from
the study.
The determination of modality switches after initial
modality choice followed the “60-day rule” used by the
USRDS (i.e., any change in modality lasting less than
60 days is not recorded as a “switch” [45] in the database).
Time-to-first modality switch was also captured by the in-
terval between the time of first switch and the time of dial-
ysis initiation. The impact of time-to-first modality switch
on Medicare expenditure was examined, specifically dur-
ing the first, second, and third years.
Calculation of costs
Our study took the Medicare perspective. Cost of treat-
ment was estimated based on Medicare expenditures.
The study period is 3 years. However, patients may have
been observed for less than 3 years due to reasons such
as death, transplantation, or loss of follow-up (i.e., cen-
sored).
Wherever applicable, Medicare expenditures were
prorated for patients with censoring due to less than
3 years of observation. This was done by dividing the ob-
served costs by their “time at risk” (i.e., time in dialysis),
defined as the time between the starting date of initial
dialysis to the date of death, transplantation, or loss to
follow-up, whichever occurred first. Aggregate cost was
also calculated as the cumulative Medicare expenditures
during “time at risk,” or the end of the study’s follow-up
period (i.e., 3 years), whichever occurred first. All costs
were inflated to the dollar value in 2004 using the medical
care component of the Consumer Price Index.
Statistical analysis
Patient characteristics were compared between differ-
ent initial modalities (i.e., hemodialysis versus peritoneal
dialysis) and among various switching patterns by t test
for continuous variables and Spearman’s chi-square test
for categoric variables. All P values reported are two-
sided; statistical significance is defined as P values less
than 0.05.
Analyses were conducted using both intent-to-treat
and as-treated approaches; our selection of analytical
method followed the methodological recommendations
in Vonesh et al [46] wherein the authors suggested that
studies using nonrandomized observational data to com-
pare mortality among ESRD patients should analyze
incident cohorts of patients from both intent-to-treat
and as-treated approaches. These recommendations for
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mortality comparisons are also relevant to cost com-
parisons since each analytical approach provides useful
information. Findings of cost comparisons from the
intent-to-treat approach attribute the observed cost dif-
ferences to a patient’s initial modality assignment with-
out considering any subsequent modality switches. As
pointed out by Vonesh et al [46], although the use of the
intent-to-treat analyses among nonrandomized ESRD
patients may preserve the selection biases originally
existing between peritoneal dialysis and hemodialysis
patients, these analyses remain informative to decision
makers, especially for clinicians who must make rec-
ommendations on an initial dialysis modality for their
patients without knowing what subsequent modality
changes the patients may experience. In addition, we em-
ployed the as-treated approach to account for modality
switches by following the actual treatment patterns of
patients over time. This approach is pertinent for studies
comparing long-term costs for ESRD patients in which
switching treatment modalities and the timing of such
switches may be as important as the assignment of the
initial modality in determining Medicare expenditures.
We first conducted multiple regression analyses to
examine the impact of the initial dialysis modality on
treatment costs using the intent-to-treat approach. We
included two samples: the first sample is a full sample,
which included all ESRD patients who met the inclu-
sion/exclusion criteria specified above; the second sam-
ple is a restrictive sample which excluded patients who
died during the 3-year study period. The purpose of the
second sample analysis was to evaluate prorated cost in
a subset of patients without potential upward bias as-
sociated with a certain treatment modality or pathway
due to higher 3-year mortality rate. This potential up-
ward bias is attributed to the exceedingly higher level of
medical expenditures found to be associated with the last
few months of life [47, 48]
We then used the as-treated approach to assess the
3-year Medicare expenditures associated with various
treatment pathways, which were characterized by the
initial dialysis modality and subsequent switching pat-
terns. Two samples were included in our analyses: the
full sample, as discussed above, and a sample with com-
plete follow-up. The latter sample excluded patients with
censoring. It therefore did not allow for any upward bias
in the prorated cost estimates caused by censoring events
such as death or transplantation.
Ordinary least square (OLS) models were used to gen-
erate age-race-comorbidity-adjusted mean expenditures
for different treatment modalities. Due to highly skewed
distribution of Medicare expenditures, we further im-
proved our multivariate analyses using the generalized
linear model (GLM) with a gamma distribution and a log
link. This estimation approach has been found to be more
robust in analysis of skewed data with strictly positive
values than the OLS model with logarithm transforma-
tion [49, 50].
Independent variables included patients’ demographic
characteristics (age, gender, and race), the primary cause
of ESRD, comorbidities, type of initial dialysis modality,
switching patterns, follow-up characteristics, and whether
the patient had Medicare as secondary payer (MSP)
anytime during the study period. The primary cause
of ESRD was categorized as diabetes, hypertension,
glomerulonephritis, or other diseases. ESRD patients’ co-
morbidities were characterized by a list of dichotomous
variables indicating whether the patient has the following
conditions: diabetes, coronary artery disease, congestive
heart failure, cerebrovascular disease, peripheral vascu-
lar disease, pericarditis, or left ventricular hypertrophy
on echocardiograph or electrocardiogram, or undernour-
ished. Switching patterns were captured by two variables:
the total number of switches over the study period, and
the time to first switch. Follow-up characteristics included
a list of dichotomous variables indicating whether the pa-
tient had a transplant, died, or was lost to follow-up during
the study period. In addition, we included dichotomous
variables of each ESRD network to account for possible
practice pattern variations across the geographic regions.
A MSP status was also assigned each patient using the
criteria recommended by the USRDS [3]; that is, if pa-
tients’ total dialysis-related expenditures were less than
$675 and the patient was not censored by day 30. MSP sta-
tus was included as an independent variable in our anal-
ysis because these patients were expected to have much
lower Medicare expenditures. Furthermore, because es-
timation of Medicare expenditures is likely to be masked
by inclusion of patients with MSP status, results from a
separate analysis excluding these patients were also re-
ported in our study.
RESULTS
Descriptive statistics
A total of 3423 ESRD incident patients from the
DMMS Wave 2 were included in our analysis. Descrip-
tive statistics are presented in Table 1. Among these pa-
tients, 1781 (52%) had peritoneal dialysis as the initial
dialysis modality and 1642 (48%) had hemodialysis. A
comparison of demographic characteristics between the
peritoneal dialysis and hemodialysis groups showed that,
on average, patients in the peritoneal dialysis group were
significantly younger (average age 57.4 years in peritoneal
dialysis versus 62.7 in hemodialysis) (P < 0.001); had a
significantly higher proportion of whites (69.6% versus
58.6%) (P < 0.001), and a lower proportion of Hispanics
(8.3% versus 10.5%) (P = 0.025). No difference in gen-
der was observed between the two groups (P = 0.49). In
terms of the ESRD etiology, the peritoneal dialysis group
had a lower proportion of patients having hypertension
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Table 1. Descriptive statistics
Peritoneal
dialysis Hemodialysis P value
Number (%) 1781 (52) 1642 (48)
Age 57.44 (15.77) 62.69 (15.70) <0.001
Age category %
≤25 2.58 1.71 <0.001
26 to 45 21.00 13.64
46 to 65 40.03 33.74
66 to 75 23.81 29.17
>75 12.58 21.74
Gender %
Male 53.62 52.44 0.49
Female 46.38 47.56
Race %
White 69.62 58.59 <0.001
African American 22.40 32.89
Other races 7.97 8.52
Ethnicity %
Hispanic 8.31 10.54 0.025
Non-Hispanic 91.69 89.46
Primary cause of end-stage
renal disease (ESRD) %
Diabetes 43.40 42.63 <0.001
Hypertension 23.02 29.42
Glomerulonephritis 10.16 6.64
Other diseases 22.74 20.34
Comorbidities %
Diabetes (history and/or
nephropathy) 47.47 49.63 0.2066
Coronary artery diseasea 32.09 38.00 0.0003
Congestive heart failure 29.51 38.30 <0.001
Cerebrovascular disease 8.19 12.42 < 0.001
Peripheral vascular
diseasesb 17.84 20.52 0.0465
Pericarditis 2.30 1.46 0.0723
Left ventricular hypertrophy
by ECG or ECHO 17.62 22.17 0.0008
Undernourished 13.74 11.45 0.0432
Dialysis modality switch
patterns %
No switch prior to censoring 46.10 56.68 <0.001
No switch 13.30 39.90
One switch 33.58 2.38
Two switches 4.44 0.61
Three and more switches 2.58 0.12
Follow-up duration
< 3 years % 67.32 58.59 <0.001
Death 45.48 46.95 0.397
Transplant 19.71 9.14 <0.001
Loss of follow-up 3.31 2.92 0.515
Medicare as second payer
(MSP) % 17.52 8.28 <0.001
Median time to first switch
months 12 9 0.138
Median time to transplant
months 16 17 0.549
Abbreviations are: ECG, electrocargiogram; ECHO, echocardiogram.
aCoronary artery disease includes history of coronary artery disease,
myocardial infarction, coronary artery bypass surgery, angioplasty, or abnormal
angiography result.
bPeripheral vascular disease includes history of peripheral vascular disease,
amputation, absent foot pulses, and claudication.
as the leading cause (23% in peritoneal dialysis versus
29% in hemodialysis) and a higher proportion having
glomerulonephritis as the leading cause (10.2% in peri-
toneal dialysis versus 6.6% in hemodialysis) (P < 0.001
for overall differences in etiology). Additionally, while
diabetes prevalence was similar in both groups, differ-
ences in the prevalence of cardiovascular disease of var-
ious manifestations were noted between the two groups
(Table 1).
Significant differences in modality switching pat-
terns were found between the peritoneal dialysis and
hemodialysis groups (P < 0.001). Approximately one
third of the ESRD patients started on peritoneal dialysis
had one switch within the 3 years following the initia-
tion of dialysis, compared to less than 3% on hemodial-
ysis. The median time to the first modality switch was
12 months in the peritoneal dialysis group and 9 months
in the hemodialysis group; however, the difference was
not statistically significant (P = 0.138). Over 7% of the
peritoneal dialysis group experienced more than one dial-
ysis modality switch, compared with less than 1% of the
hemodialysis group. Kidney transplantation was reported
in 19.7% of the peritoneal dialysis group and 9.1% of the
hemodialysis group (P < 0.001), while no significant dif-
ference was found in the median time to transplant (16
and 17 months for the peritoneal dialysis and hemodial-
ysis groups, respectively (P = 0.549). No difference was
found between the two groups in 3-year mortality (P =
0.397) or censoring due to loss of follow-up (P = 0.515).
A significantly higher proportion of peritoneal dialysis
patients had MSP status than did hemodialysis patients
(17.5% vs. 8.3%) (P < 0.001).
Bivariate analyses of Medicare expenditures and
treatment modalities
Table 2 reports comparisons of the unadjusted annual
Medicare expenditures by initial modalities as well as by
switching patterns. The average annual Medicare expen-
diture for an ESRD patient started on peritoneal dial-
ysis was $53,277 (95% CI $50,626 to $55,927), which
was significantly lower than the annual average of those
who started on hemodialysis ($72,189) (95% CI $67,513
to $76,865) (P < 0.001). We also compared Medicare
expenditures by switching patterns, categorized as (1)
hemodialysis, no switch; (2) peritoneal dialysis, no switch;
(3) hemodialysis, at least one switch; and (4) peritoneal
dialysis, at least one switch. Compared to the “hemodialy-
sis, no switch” group 1 (mean = $72,185, 95% CI $67,377
to $76,992), we found that group 2 (peritoneal dialysis,
no switch) had a significantly lower annual Medicare ex-
penditure (mean = $44,111, 95% CI $40,746 to $47,477)
(P < 0.001). Expenditures for group 3 (hemodialysis at
least one switch) ($72,335, 95% CI $59,410 to $85,260)
and group 4 (peritoneal dialysis at least one switch)
($66,639, 95% CI $62,535 to $70,743) were not signifi-
cantly different compared to group 1 (hemodialysis no
switch, reference group).
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Table 2. Total Medicare expenditures
Mean 95% CI P value
Intent-to-treat analysis
Unadjusted
Peritoneal dialysis $53,277 ($50,626-$55,927) <0.001
Hemodialysis $72,189 ($67,513-$76,865)
Adjusted, with Medicare
as secondary payer
Peritoneal dialysis $56,807 ($53,205-$60, 410) <0.001
Hemodialysis $68,253 ($64,490-$72, 016)
Adjusted, without Medicare
as secondary payer
Peritoneal dialysis $60,894 ($58,032-$63,755) <0.001
Hemodialysis $71,634 ($68,795-$74,474)
As-treated analysis
Unadjusted
Group 1 $72,185 ($67,377-$76,992)
Group 2 $44,111 ($40,746-$47,477) <0.001
Group 3 $72,335 ($59,410-$85,260) 0.991
Group 4 $66,639 ($62,535-$70,743) 0.154
Adjusted, with Medicare
as secondary payer
Group 1 $68,209 ($64,395-$72,023)
Group 2 $48,446 ($43,699-$53,194) <0.001
Group 3 $76,007 ($54,863-$97,150) 0.477
Group 4 $68,531 ($62,894-$74,167) 0.926
Adjusted without Medicare
as secondary payer
Group 1 $71,287 ($68420-$74,155)
Group 2 $51,079 ($47182-$54,976) <0.001
Group 3 $80,244 ($64655-$95,833) 0.269
Group 4 $71,883 ($67768-$75,997) 0.818
Group 1 is hemodialysis with no switch; group 2 is peritoneal dialysis with no
switch; group 3 is hemodialysis with at least one switch; and group 4 is peritoneal
dialysis with at least one switch.
Multivariate analysis
To adjust for differences in patient characteristics, we
conducted multivariate analyses to account for the differ-
ences between the peritoneal dialysis and hemodialysis
groups. We first used OLS models to obtain the adjusted
mean for each treatment modality reported above, adjust-
ing for differences in age, race, comorbidity, and MSP sta-
tus for analyses, including patients with MSP status. For
analyses excluding patients with MSP status, age-race-
comorbidity adjusted means were reported (Table 2).
After adjusting for patients’ age, race, comorbidity and
MSP status, the adjusted mean annual expenditures in-
creased to $56,807 for patients who started on peritoneal
dialysis and decreased to $68,253 for those who started
on hemodialysis, although the difference remained to be
statistically significant (P < 0.001). We also reported the
adjusted mean Medicare expenditures by switching pat-
terns categorized above. In general, for those who did
not have a switch of dialysis modality, the adjusted mean
was higher than the unadjusted for the peritoneal dialysis
patients ($48, 446 vs. $44,111) and lower for the hemodial-
ysis patients ($68,209 vs. $72,185). For those who had one
or more switch, the adjusted means were higher for both
peritoneal dialysis and hemodialysis groups ($68,531 vs.
$66,639 for peritoneal dialysis and $76,007 vs. $72,335 for
hemodialysis). Similar patterns were found when patients
with MSP status were excluded.
Results from the GLM models of the intent-to-treat
analyses of factors affecting expenditure and the impact
of initial modality assignment are presented in Table 3.
A variety of factors have been found to affect expen-
diture independently, including advanced age, race, eti-
ology of ESRD and selected comorbidities. ESRD net-
work had no significant effect on expenditures within this
patient population. Medicare expenditure was found to
be significantly lower for patients with peritoneal dial-
ysis as the initial modality, compared with hemodialysis
in both the full sample (P < 0.001) and the restricted
sample (P = 0.004). Medicare expenditures for the peri-
toneal dialysis and hemodialysis groups were calculated
and compared using the coefficients estimated from the
GLM model. The projected mean annual Medicare ex-
penditure was $75,811 (SD = 40,978) and $54,857 (SD =
33,596) for patients whose initial dialysis was hemodial-
ysis and peritoneal dialysis, respectively, based on the
full sample estimates. That is, the projected annual Medi-
care expenditure was significantly higher ($20,954) (P <
0.001) for the hemodialysis group than for the peritoneal
dialysis group. The analysis based on the restricted sam-
ple showed a similar result but with a smaller difference;
the projected annual Medicare expenditure was $49,130
(SD = 18,943) for the hemodialysis group and $37,139
(SD = 18,047) for the peritoneal dialysis group. t tests
showed that the difference between the hemodialysis and
peritoneal dialysis group ($11,982) was statistically signif-
icant (P < 0.001). Subgroup analyses excluding patients
with MSP status showed a similar finding, although the
magnitude of the differences differed. The difference in
the predicted annual Medicare expenditure between the
hemodialysis and peritoneal dialysis group was $15,751
with the full sample and $12,522 with the restricted sam-
ple; both differences were statistically significant.
Table 4 summarizes results from our analyses of the
initial modalities and the switching patterns on cost us-
ing the as-treated approach for the full sample and for
the complete follow-up sample. The same pattern of ef-
fect of age, race, etiology of ESRD and select comor-
bidities emerges as in the intent to treat approach shown
above.
The regression coefficients associated with the interac-
tion terms of the initial modality (“peritoneal dialysis”
or “hemodialysis”) and the time to first switch can be
used to estimate the cost differences between ESRD pa-
tients who started on peritoneal dialysis and had no sub-
sequent modality switch and those who had peritoneal
dialysis as initial modality and switched to hemodialy-
sis. Further delineations according to time interval when
the switch occurred were analyzed at the following inter-
vals: during the first year, the second year, and the third
year.
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Table 3. Multiple regression models—The intent-to-treat approach
Full sample Restricted sample
With MSP Without MSP With MSP Without MSP
(N = 3180) (N = 2773) (N = 1706) (N = 1501)
Age (reference group age >75 years old)
≤ 45 −0.133 −0.041 −0.096 −0.112
46 to 65 −0.304a −0.147a −0.191b −0.190b
66 to 75 0.028 0.013 0.065 0.043
Male −0.074 −0.038 −0.003 −0.112
Race (reference group white)
Black 0.193a 0.071b 0.008 −0.016
Other race 0.005 0.027 −0.041 −0.058
Hispanic 0.068 −0.017 0.167b 0.024
Primary cause of ESRD (reference group diabetes)
Hypertension −0.178b −0.152a −0.059 −0.121b
Glomerulonephritis −0.208b −0.148b −0.198b −0.212a
Other diseases −0.071 −0.065 −0.156b −0.124b
Comorbidities
Coronary artery disease 0.102 0.043 −0.001 0.033
Congestive heart failure 0.124b 0.115a 0.223a 0.193a
Cerebrovascular disease 0.033 0.084 0.071 0.093
Peripheral vascular diseases 0.058 0.091b 0.181b 0.185b
Pericarditis −0.016 0.084 −0.183 −0.130
Left ventricular hypertrophy by ECG or ECHO 0.065 0.026 0.081 0.040
Undernourished 0.114 0.033 0.063 0.017
Initial modality: Peritoneal dialysis −0.187b −0.191a −0.114b −0.195a
Loss of follow-up −0.593a −0.587a −0.227b −0.572a
Death 0.760a 0.624a N/A N/A
MSP status −0.990a N/A −2.111a N/A
Abbreviations are: MSP, Medicare as secondary payer; ECG, electrocardiogram; ECHO, echocardiogram; ESRD, end-stage renal disease.
aIndicates significance at P < 0.001.
bIndicates statistically significant difference at P < 0.05.
Analyses based on both the full sample and the com-
plete follow-up sample showed that, compared with the
hemodialysis group who did not have any switch, the
peritoneal dialysis group with no switch had significantly
lower cost (P < 0.001), regardless whether patients with
MSP status were excluded from the analyses. However,
when a switch occurred in patients on peritoneal dialy-
sis as an initial modality, the impact on expenditure was
dependent on the time when the switch occurred with
a shorter time on peritoneal dialysis before the switch
favoring higher expenditures. Comparisons among pa-
tients in the peritoneal dialysis group showed that com-
pared with peritoneal dialysis patients who did not have
any switch, those who switched within the first 2 years
following the initiation of dialysis had a significantly
higher Medicare expenditure, whereas no significant dif-
ference was found between the peritoneal dialysis no-
switch group and the peritoneal dialysis patients who
switched to hemodialysis in the third year (P = 0.636
with MSP and P = 0.493 without MSP in the full sample)
(P = 0.162 with MSP and P = 0.136 without MSP in the
complete follow-up sample). Additionally, in the analy-
ses including all ESRD patients regardless of their MSP
status, Medicare expenditures were significantly higher
for ESRD patients who had more than one switch than
for those who had one or no switch.
Further analyses of time to switch on cost are sum-
marized in Table 5. Compared with hemodialysis patient
with no modality switch, the projected 3-year Medicare
expenditures were significantly lower for peritoneal dial-
ysis patients who did not have a modality switch through-
out the study period; the projected 3-year differences
were −$88,973 (P < 0.001) and −$68,045 (P < 0.001)
in the full and complete follow-up samples, respectively,
for analyses including patients with MSP status. The
3-year differences from the subgroup analyses excluding
the MSP patients were reduced to −$73,141 (P < 0.001)
and −$67,451 (P < 0.001), respectively. Peritoneal dial-
ysis patients who switched to hemodialysis in year 1 of
dialysis had a significantly higher Medicare expenditure
than hemodialysis patients with no switch; the projected
difference in the 3-year expenditure ranged from $34,410
(P < 0.001) with MSP and $33,506 (P < 0.001) without
MSP in the complete follow-up sample to $44,610 (P <
0.001) with MSP and $46,786 (P < 0.001) without MSP
in the full sample. The projected 3-year Medicare expen-
ditures for peritoneal dialysis patients who switched to
hemodialysis after the first year were significantly lower
than those for hemodialysis patients who had no switch;
cost reductions of $45,540 (P < 0.001) ($47,132) (P <
0.001 without MSP) and $108,433 (P < 0.001) ($109,646)
(P < 0.001 without MSP) were found in the full sample for
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Table 4. Multiple regression models—The as-treated approach
Full sample Complete follow-up sample
With MSP Without MSP With MSP Without MSP
(N = 3180) (N = 2773) (N = 1168) (N = 1160)
Age (reference group age >75 years old)
≤45 −0.124 −0.082 −0.076 −0.077
46 to 65 −0.304a −0.164a −0.194b −0.206a
66 to 75 0.009 0.008 0.005 0.002
Male −0.066 −0.037 −0.072b −0.071b
Race (reference group white)
Black 0.145b 0.038 −0.019 −0.024
Other race 0.006 0.045 0.012 −0.009
Hispanic 0.051 −0.039 0.044 0.016
Primary cause of ESRD (reference group diabetes)
Hypertension −0.158b −0.135a −0.079 −0.101b
Glomerulonephritis −0.183b −0.131b −0.171b −0.178b
Other disease −0.067 −0.068 −0.093 −0.095
Comorbidities
Coronary artery disease 0.089 0.030 0.032 0.028
Congestive heart failure 0.114b 0.110b 0.173a 0.172a
Cerebrovascular disease 0.047 0.098b 0.054 0.056
Peripheral vascular disease 0.044 0.082b 0.217a 0.188a
Pericarditis −0.037 0.072 0.016 0.021
Left ventricular hypertrophy by ECG or ECHO 0.035 0.011 0.060 0.050
Undernourished 0.119 0.033 0.005 −0.010
Dialysis modality (reference group hemodialysis with no switch)
Peritoneal dialysis −0.339a −0.388a −0.492a −0.505a
Peritoneal dialysis switch, year 1 0.530a 0.587a 0.674a 0.684a
Peritoneal dialysis switch, year 2 0.249b 0.253a 0.448a 0.454a
Peritoneal dialysis switch, year 3 −0.055 −0.048 0.106 0.111
More than one switch 0.422a 0.426a 0.535a 0.544a
Censoring variables
Loss of follow-up −0.604a −0.514a N/A N/A
Transplantation −0.254a −0.024 N/A N/A
Death 0.704a 0.618a N/A N/A
MSP status −0.852a N/A −1.795∗∗ N/A
Abbreviations are: MSP, Medicare as secondary payer; ECG, electrocardiogram; ECHO, echocardiogram; ESRD, end-stage renal disease.
aIndicates significance at P < 0.001.
bIndicates statistically significant difference at P < 0.05.
peritoneal dialysis patients who switched to hemodialy-
sis during the second and third years, respectively. Anal-
yses based on the complete follow-up sample showed
a similar trend but at a smaller magnitude; the cost re-
ductions were $15,469 (P < 0.001) ($16,692) (P < 0.001
without MSP) and $63,660 (P < 0.001) ($64,394) (P <
0.001 without MSP) for peritoneal dialysis patients who
switched modalities in year 2 and year 3, respectively.
No significant differences in the 3-year Medicare expen-
ditures were found for patients who had more than one
switch throughout the study period (P = 0.7609 with MSP
and P = 0.2868 without MSP in the full sample) (P =
0.7651 with MSP and P = 0.6102 without MSP in the
complete follow-up sample) regardless of their starting
dialysis modality.
Compared with elderly ESRD patients over 75 years of
age, we found significantly lower expenditures for ESRD
patients 45 years of age or younger [due to the small
number of observations in the 0 to 25 year age group
(i.e., less than 3%), we combined two age groups, 0 to
25 and 26 to 45, to form the younger age group in our
analyses] and for the 46 to 65 years age group. No sig-
nificant differences were found between the most elderly
group and the age group of 66 to 75 years (P = 0.668 in
the full sample and P = 0.382 in the restricted sample
in Table 3, with MSP) (P = 0.889 in the full sample and
P = 0.928 in the complete follow-up sample in Table 4,
with MSP). No statistically significant differences were
found between patients of Hispanic and non-Hispanic
ethnicity. Higher expenditures were found for African
American patients compared with white ESRD patients.
However, this relationship was not consistently statisti-
cally significant. The majority of our analyses found no
racial difference between whites and other races (i.e.,
non-white and non-African American). Medicare ex-
penditures were significantly lower for those with hy-
pertension, or glomerulonephritis as the leading cause
compared with ESRD patients who reported having dia-
betes as the leading cause of ESRD. In addition, no sta-
tistically significant differences were found when com-
paring Medicare expenditures across ESRD networks
(data not shown). Similar patterns were found in analyses
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Table 5. Projected 3-year Medicare expenditures by treatment modalities and switching patterns
Differences with
Adjusted mean (SD) hemodialysis % change P value
Full sample, including MSP (N = 3180)
Start on hemodialysis $223,670 (115,588) — —
Peritoneal dialysis, no switch $134,698 (88,778) −$88,973 −39.8% <0.001
Peritoneal dialysis, switch, year 1 $268,280 (132,799) $44,610 19.9% <0.001
Peritoneal dialysis, switch, year 2 $178,130 (86,238) −$45,540 −20.4% <0.001
Peritoneal dialysis, switch, year 3 $115,237 (51,838) −$108,433 −48.5% <0.001
More than one switch $227,112 (114,327) $3,442 1.5% 0.7609
Full sample, excluding MSP (N = 2773)
Start on hemodialysis $221,880 (86,728) — — —
Peritoneal dialysis, no switch $148,740 (61,480) −$73,141 −33.0% <0.001
Peritoneal dialysis, switch, year 1 $268,666 (98,183) $46,786 21.1% <0.001
Peritoneal dialysis, switch, year 2 $174,748 (64,719) −$47,132 −21.2% <0.001
Peritoneal dialysis, switch, year 3 $112,234 (41,821) −$109,646 −49.4% <0.001
More than one switch $212,811 (85,741) −$9,070 − 4.1% 0.2868
Complete follow-up, including MSP (N = 1168)
Start on hemodialysis $157,055 (35,877) — — —
Peritoneal dialysis, no switch $89,010 (22,279) −$68,045 −43.3% <0.001
Peritoneal dialysis, switch, year 1 $191,465 (41,340) $34,410 21.9% <0.001
Peritoneal dialysis, switch, year 2 $141,586 (25,856) −$15,469 −9.8% <0.001
Peritoneal dialysis, switch, year 3 $93,396 (15,504) −$63,660 −40.5% <0.001
More than one switch $155,627 (36,118) −$1,428 −0.9% 0.7651
Complete follow-up, excluding MSP (N = 1160)
Start on hemodialysis $157,699 (34,223) — — —
Peritoneal dialysis, no switch $90,248 (18,245) −$67,451 −42.8% <0.001
Peritoneal dialysis, switch, year 1 $191,205 (39,676) $33,506 21.2% <0.001
Peritoneal dialysis, switch, year 2 $141,007 (24,125) −$16,692 −10.6% <0.001
Peritoneal dialysis, switch, year 3 $93,305 (15,609) −$64,394 −40.8% <0.001
More than one switch $155,372 (34,793) −$2,327 −1.5% 0.6102
MSP is Medicare as secondary payer.
excluding patients with MSP status. For analyses includ-
ing the MSP patients, ESRD patients who had an MSP
status anytime during the study period had much lower
Medicare expenditures, as expected.
The relationship between Medicare expenditures and
variables characterizing patient censoring or a shorter
follow-up period showed the expected patterns. Patients
who were censored due to loss of follow-up had signifi-
cantly lower expenditures, both in the intent-to-treat and
as-treated analyses. Death during the evaluation period
was associated with significantly higher prorated expendi-
tures in both the intent-to-treat (P < 0.001) and as-treated
analyses (P < 0.001) using the full sample. The analyses
taking the as-treated approach on the full sample allowed
us to assess the effect on the duration of follow-up, as well
as the transplantation status. Significantly lower levels of
Medicare expenditures were found in patients who had
renal transplantation anytime during the study period
(P < 0.001) in the analyses including MSP status
(Table 4).
DISCUSSION
The results of the present study can be summarized
as follows. First, in an intent-to-treat analysis Medicare
expenditures are lower for patients who initiate dialy-
sis on peritoneal dialysis compared to those who start
dialysis on hemodialysis. Specifically, we found that the
annual Medicare expenditures were 23% to 27% lower
for ESRD patients who were prescribed peritoneal dial-
ysis as the initial modality compared to those of pa-
tients who started on hemodialysis. Second, the favorable
expenditure profile of peritoneal dialysis is maintained
when an as treated analysis is performed. Third, when
modality switches are taken into account, patients who
start on peritoneal dialysis and switch to hemodialysis
within the first year of dialysis therapy lose the advanta-
geous expenditure profile compared to patients who start
on hemodialysis with no switch. Finally, when modality
switch occurs beyond the first year on peritoneal dialysis,
the advantageous expenditure profile of having started
on peritoneal dialysis is maintained, albeit attenuated
compared to patients who start on peritoneal dialysis and
stay on peritoneal dialysis.
Previous studies of comparative expenditure on the
two modalities had shown an almost consistent pattern of
lower annual cost with peritoneal dialysis in the United
States and other countries [3, 5, 6, 9, 11–16, 18, 20, 21, 37–
41]. Most of these studies examined overall costs without
consideration of the modality switches that are part of
the clinical journey of the patient. It is recognized that
transfers between types of renal replacement therapy oc-
cur at varying frequencies. Patients who start on peri-
toneal dialysis have a higher rate of transplantation than
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patients who start on hemodialysis in the present study as
well as in the general USRDS population [51]. Transfers
between dialysis modalities may result in substantial cost
increase driven by repeated start-up costs associated with
initiation of a treatment modality. This has heretofore
been documented in a single center study from Canada
[52]. The present study is the first population-based study
to examine the impact of modality switch as well as the
time of modality switch on Medicare expenditures in pa-
tients on dialysis. Transfer between dialytic modalities
also occurs for a variety of reasons, including those re-
lated to the technical aspects of the modality in question.
Patients who start on hemodialysis transfer to peritoneal
dialysis when they exhaust vascular access sites, when
they are intolerant of hemodialysis because of cardiovas-
cular instability or by patient choice. Similarly, patients
starting on peritoneal dialysis transfer to hemodialysis
because of therapy complications such as malfunctioning
catheters, infections, or patient choice. It is important to
note that the causes of transfer from peritoneal dialysis
to hemodialysis are potentially preventable when current
care guidelines are followed. Rates of modality transfer
have been declining significantly in recent years [43].
The Medicare expenditures estimated from the full
sample are likely to be overestimated because the higher
costs associated with death or renal transplantation pro-
cedures may have been inflated when the estimates were
prorated to 3-year expenditures. This phenomenon was
reflected in the finding of lower prorated expenditures
for peritoneal dialysis patients who switched in the third
year compared to the expenditures of patients who did
not have a switch in the full-sample, as-treated analysis.
Our study suggests that peritoneal dialysis patients
who switched within the first year had higher treatment
costs than those who switched later. Information on the
reasons of early modality switch will help clinicians un-
derstand the factors associated with early switching and
develop treatment strategies to better manage ESRD pa-
tients. Unfortunately, such information was not provided
in the baseline or follow-up questionnaires in the DMMS
Wave 2. Treatment strategies to reduce early switching
from peritoneal dialysis to hemodialysis will significantly
lower treatment cost. Such strategies may include use of
automated peritoneal dialysis [43] and incorporation of
therapy advances [53–55].
The perspective of this study is that of the Medicare
ESRD program; therefore, we included all medical ex-
penses covered by Medicare—regardless of whether the
expenses were specific to ESRD care or not. We delib-
erately chose not to exclude patients with an MSP status
and/or a kidney transplant because of the financial impli-
cations these patients’ expenditures had to the Medicare
ESRD program during the 3-year study period. Specifi-
cally, although ESRD patients with active MSP statuses
have much lower Medicare expenditures, they will have
Medicare as their primary payer immediately after the
18-month waiting period. Since the 18-month waiting pe-
riod policy was in effect during the time of our study pe-
riod, we expected Medicare to assume the role of primary
payer during the second half of the 3-year study period.
A dichotomous variable representing patients’ MSP sta-
tuses was added in our multivariate analyses to control
for their effects on Medicare expenditures. In addition,
we presented results from a separate set of analyses ex-
cluding patients with MSP status and found the results
to be similar to the previous findings. We also included
patients undergoing transplantation in our analyses since
Medicare is required to cover the medical expenses of
patients with a successful kidney transplant for 3 years
[56]. That our cost analysis assumed the Medicare per-
spective, not a provider’s (such as a dialysis center or a
hospital) perspective is critical to the interpretation of
our results because a cost element to Medicare may not
necessarily be a cost element to a provider. For example,
the switching from one modality to another will incur ad-
ditional expenditures (cost) to Medicare as a payer, but
may bring in more revenue than cost to a provider.
Medicare payment associated with alternative modal-
ities has been estimated in a previous USRDS study [3].
However, only the initial modality was considered in that
study. Further the study did not adjust for the patient
differences in the peritoneal dialysis and hemodialysis
groups, nor did it consider modality switches. Compar-
ison of cost estimates showed that the unadjusted per
capita Medicare expenditures for peritoneal dialysis and
hemodialysis were $72K and $53K in our study, respec-
tively, and $60K and $52K, respectively (in 2004 dollars)
in the previous study. The discrepancies may be due to dif-
ferences in the inclusion/exclusion criteria—the previous
USRDS study excluded MSP patients and included a mix
of prevalent and incident patients between 1993 and 1997.
After excluding patients with MSP status in our study,
our estimates became $74K for hemodialysis patients and
$58K for peritoneal dialysis patients, which were higher
than the estimates in the previous study of peritoneal
dialysis and were substantially higher for hemodialysis.
The relatively larger difference in estimates of hemodial-
ysis cost may be attributable to a greater cost increase
in medical procedures necessary for hemodialysis treat-
ment, such as vascular access, anemia management, and
control of hyperparathyroidism, during the time frame of
our study (1996 to 2000) compared to that of the USRDS
study (1993 to 1997). It should be noted that the lower
costs of peritoneal dialysis are likely to be due to the fact
that peritoneal dialysis patients are in generally younger
and had fewer comordibities. After adjusting for patients’
age, race, and comorbidities, the cost difference between
peritoneal dialysis and hemodialysis was reduced by ap-
proximately one third, although the difference remained
statistically significant.
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Costs in our study were measured by Medicare expen-
ditures. It is possible that we may have underestimated
the true costs of caring for ESRD patients since not all
costs were included. Costs such as patients’ copayments
and deductibles, and outpatient prescription drug costs
(with the exception of erythropoietin and immunosup-
pressive drugs, which were covered by Medicare) were
not included in our study. However, we did not expect
these exclusions to bias the cost differences observed in
our study since these costs should be similar between pa-
tients receiving peritoneal dialysis and hemodialysis.
Some may argue that a more appropriate study per-
spective is a societal perspective and that indirect costs
such as time lost from work for the ESRD patients as
well as their family caregivers should be considered. In-
deed, cost studies taking a societal perspective can better
reflect the true costs. Unfortunately, the USRDS DMMS
Wave 2 does not provide sufficient information to allow
such assessments.
The primary goal of our study was to compare Medi-
care expenditures between initial dialysis modalities and
among selected treatment pathways. We found that ag-
gregated 3-year Medicare expenditures were lower in
ESRD patients with peritoneal dialysis as the initial
modality. A caveat is that early switch to hemodialysis,
defined as switch in the first year of therapy, was associ-
ated with higher aggregated Medicare expenditures. This
caveat emphasizes the importance of optimizing patient
care to eliminate or reduce technical causes of switch
and thus avoid contravention of a patient’s initial therapy
choice. It is clear from large cohort studies that mechan-
ical catheter dysfunction and infections are major causes
of modality transfer in the first year on peritoneal dial-
ysis [43]. Either is amenable to preventive interventions
such as the selection of appropriate surgical techniques or
the application of infection prophylaxis practices, respec-
tively. Although these findings emphasize the importance
of high quality of care and the cost implications of good
clinical practice, our study focuses on cost comparisons
among treatment modalities and pathways as practiced
and does not intend to use cost estimates as a quality
benchmark. Future study should use the accepted quality
indicators for ESRD patients to explore the association
between modality switch and quality of care.
CONCLUSION
We have demonstrated that over the 3-year period
evaluated, compared to patients who initiate and main-
tain dialysis with hemodialysis, patients who initiate and
maintain dialysis with peritoneal dialysis, or who initiate
dialysis on peritoneal dialysis and switch to hemodialysis
beyond 1 year of therapy, exhibit a significantly lower ag-
gregated 3-year Medicare expense profile. This is true in-
clusive of incremental expenses associated with modality
conversion such as new access placement and patient re-
training. However, patients who start on peritoneal dial-
ysis and switch to hemodialysis within the first year of
dialysis therapy lose this advantageous expenditure pro-
file.
These results suggest that peritoneal dialysis is the
more economically advantageous initial dialysis modal-
ity from an expenditure perspective. In addition, a longer
time on peritoneal dialysis better sustains this economic
advantage even in the case of a modality switch with the
resultant costs inherent in the modality switch and the
use of the higher cost hemodialysis modality. Efforts to
reduce preventable causes of early modality switch in pa-
tients who start on peritoneal dialysis have the potential
to further magnify the financial advantages to Medicare.
This observation may define the value of special coverage
and reimbursement for such efforts.
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